Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
Open Access
- 20 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 11 (8), 1645-1666
- https://doi.org/10.1007/s13300-020-00855-5
Abstract
Type 2 diabetes is characterised by chronic hyperglycaemia and variable degrees of insulin deficiency and resistance. Hyperglycaemia and elevated fatty acids exert harmful effects on β-cell function, regeneration and apoptosis (gluco-lipotoxicity). Furthermore, chronic hyperglycaemia triggers a vicious cycle of insulin resistance, low-grade inflammation and a cascade of pro-atherogenic processes. Thus, timely near to normal glucose control is of utmost importance in the management of type 2 diabetes and prevention of micro- and macroangiopathy. The majority of patients are multimorbid and obese, with critical comorbidities such as cardiovascular disease, heart failure and chronic kidney disease. Recently published guidelines therefore recommend patient-centred risk/benefit-balanced use of oral glucose-lowering drugs or a glucagon-like peptide 1 (GLP-1) receptor agonist, or switching to insulin with glycated haemoglobin (HbA1c) out of target. This article covers the indications of early insulin treatment to prevent diabetes-related complications, particularly in subgroups with severe insulin deficit, and to achieve recovery of residual β-cell function. Furthermore, the individualised, risk/benefit-balanced, timely initiation of insulin as second and third option is analysed. Timely insulin initiation may prevent diabetes progression, reduce diabetes-related complications and has less serious adverse effects. Basal insulin is the preferred option in most clinical situations with consequences of undertreatment of chronic hyperglycaemia.Keywords
Funding Information
- Sanofi
This publication has 150 references indexed in Scilit:
- Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 DiabetesDiabetes Technology & Therapeutics, 2013
- Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetesActa Diabetologica, 2013
- An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemiaDiabetes, Obesity and Metabolism, 2011
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialThe Lancet, 2010
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia, 2009
- Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes MellitusJAMA, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Relationship between β‐cell mass and diabetes onsetDiabetes, Obesity and Metabolism, 2008
- Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemiaThe Journal of Experimental Medicine, 2008
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006